https://www.selleckchem.com/pr....oducts/cid44216842.h
Antiplatelet therapy for neonates and infants is often extrapolated from the adult experience, based on limited observation of agonist-induced neonatal platelet hypoactivity and poor understanding of flow shear-mediated platelet activation. Therefore, thrombotic events due to device-associated disturbed flow are inadequately mitigated in critically ill neonates with indwelling umbilical catheters and infants receiving cardiovascular implants. Whole blood (W, platelet-rich plasma (PRP), and gel-filtered platelets (GFP) were prepare
Like
Comment
Share
